Results 51 to 60 of about 186,179 (282)

Cytokine-induced killer cells/dendritic cells and cytokine-induced killer cells immunotherapy for the treatment of esophageal cancer in China: a meta-analysis

OncoTargets and Therapy, 2017
Immunotherapy based on cytokine-induced killer cells or combination of dendritic cells and cytokine-induced killer cells (CIK/DC-CIK) showed promising clinical outcomes for treating esophageal cancer (EC). However, the clinical benefit varies among previous studies.
Yan Liu, Ying Mu, Anqi Zhang, Shaoda Ren, Weihua Wang, Jiaping Xie, Yingxin Zhang, Changhui Zhou   +7 more
openaire   +4 more sources

Adjuvant alternative cytokine-induced killer cell combined with natural killer cell immunotherapy improves the prognosis of post-mastectomy breast cancer

Frontiers in Immunology, 2022
Breast cancer is one of the most common cancers in women. Triple-negative breast cancer (TNBC) has a significantly worse prognosis due to the lack of endocrine receptors including estrogen receptor (ER), progesterone receptor (PR) and human epidermal ...
Xinyi Yang, Xinyi Yang, Desheng Weng, Desheng Weng, Qiuzhong Pan, Qiuzhong Pan, Tong Xiang, Tong Xiang, Chaopin Yang, Chaopin Yang, Zhengrong Wu, Minxing Li, Minxing Li, Songzuo Xie, Songzuo Xie, Yan Tang, Yan Tang, Jianchuan Xia, Jianchuan Xia, Jingjing Zhao, Jingjing Zhao   +20 more
doaj   +1 more source

Natural killer (NK) cells and their involvement in different types of cancer. Current status of clinical research [PDF]

, 2017
Natural killer cells are the main agents of innate immunity. Since 1970, various studies have repeatedly confirmed their involvement in decreasing local tumor growth and also decreasing the risk of metastasis, due to their cytotoxic effects and also ...
Moldovan, Adina D., Tanase, Cristiana, Zaharescu, Isadora   +2 more
core   +4 more sources

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study

Clinical & Translational Immunology, 2021
Objectives Although axitinib has achieved a preferable response rate for advanced renal cell carcinoma (RCC), patient survival remains unsatisfactory. In this study, we evaluated the efficacy and safety of a combination treatment of axitinib and a low ...
Meng‐Jia Song, Qiu‐Zhong Pan, Ya Ding, Jianxiong Zeng, Pei Dong, Jing‐Jing Zhao, Yan Tang, Jingjing Li, Zhiling Zhang, Junyi He, Jieying Yang, Yue Huang, Ruiqing Peng, Qi‐Jing Wang, Jia‐Mei Gu, Jia He, Yong‐Qiang Li, Shi‐Ping Chen, Rongxing Huang, Zi‐Qi Zhou, Chaopin Yang, Yulong Han, Hao Chen, Heping Liu, Shangzhou Xia, Yang Wan, De‐Sheng Weng, Liming Xia, Fang‐Jian Zhou, Jian‐Chuan Xia   +29 more
doaj   +1 more source

Advances in research based on antibody-cell conjugation

Frontiers in Immunology, 2023
Antibody-cell conjugation (ACC) technology is a new research direction in medicine and biotechnology in recent years. The concept of ACC was proposed by Hsiao et al.
Xiaoxuan Ma, Jian Jiang, Xiaoye An, Wanting Zu, Chi Ma, Zhuo Zhang, Yaci Lu, Lijing Zhao, Lisheng Wang   +8 more
doaj   +1 more source

Human Cytokine-Induced Memory-Like Natural Killer Cells [PDF]

Journal of Innate Immunity, 2015
Natural killer (NK) cells are innate lymphoid cells that are important for host defense against infection and mediate antitumor responses. Recent reports from several laboratories have identified that NK cells can remember a prior activation event and consequently respond more robustly when restimulated, a property termed innate NK cell memory. NK cell
Melissa M. Berrien-Elliott, Julia A. Wagner, Todd A. Fehniger   +2 more
openaire   +2 more sources

Acute exercise mobilizes NKT-like cells with a cytotoxic transcriptomic profile but does not augment the potency of cytokine-induced killer (CIK) cells

Frontiers in Immunology, 2022
CD3+/CD56+ Natural killer (NK) cell-like T-cells (NKT-like cells) represent <5% of blood lymphocytes, display a cytotoxic phenotype, and can kill various cancers. NKT-like cells can be expanded ex vivo into cytokine-induced killer (CIK) cells, however
Tiffany M. Zúñiga, Forrest L. Baker, Kyle A. Smith, Helena Batatinha, Branden Lau, Michael P. Gustafson, Emmanuel Katsanis, Emmanuel Katsanis, Emmanuel Katsanis, Emmanuel Katsanis, Emmanuel Katsanis, Richard J. Simpson, Richard J. Simpson, Richard J. Simpson, Richard J. Simpson   +14 more
doaj   +1 more source

Effector Functions of Natural Killer Cell Subsets in the Control of Hematological Malignancies. [PDF]

, 2015
Treatment of hematological malignant disorders has been improved over the last years, but high relapse rate mainly attributable to the presence of minimal residual disease still persists.
Biassoni, Biron, Björklund, Brodin, Bryceson, Burns, Campbell, Cooley, Cooper, Cooper, Curti, Davies, Di Santo, Di Santo, Farag, Fehniger, Fogler, Foley, Freud, Gasser, Gilfillan, Grimm, Guethlein, Herberman, Huntington, Joncker, Kiessling, Killig, King, Kröger, Lajoie, Lanier, Leong, Ljunggren, Lowe, Lundqvist, Mancusi, McQueen, Miller, Moretta, Moretta, Moretta, Nguyen, Oevermann, Ouyang, Perussia, Phillips, Romagnani, Romee, Rosenberg, Rosenberg, Rosenberg, Ruggeri, Santoni, Stabile, Stabile, Stern, Stringaris, Thielens, Torelli, Trinchieri, Trinchieri, Vago, Valés-Gómez, Venstrom, Vivier, Whitelaw, Zorn   +67 more
core   +1 more source

Case report: Dendritic cell-cytokine induced killer cell therapy in subjects with chronic lymphocytic leukemia and peritoneal cancer

Frontiers in Medicine, 2023
This study aimed to characterize the safety and efficacy of DC-CIK therapy in two patients with previously treated chronic lymphocytic leukemia or peritoneal cancer, respectively.
Brian Mehling, DongCheng Wu, Ellen O’Gorman, Daniel Sheridan, Doreen Santora, Renata Mihályová   +5 more
doaj   +1 more source

Obinutuzumab-mediated high-affinity ligation of FcγRIIIA/CD16 primes NK cells for IFNγ production [PDF]

, 2017
Natural killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC), based on the recognition of IgG-opsonized targets by the low-affinity receptor for IgG FcγRIIIA/CD16, represents one of the main mechanisms by which therapeutic antibodies
Battella, Simone, Belardinilli, Francesca, Capuano, Cristina, Galandrini, Ricciarda, Giannini, Giuseppe, Molfetta, Rosa, Palmieri, Gabriella, Paolini, Rossella, Pighi, Chiara, Santoni, Angela   +9 more
core   +2 more sources